• Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Immunomodulator
  • Antineoplastic agent
  • Imatinib
  • Infliximab